7News Just In
Von Hippel-Lindau disease is a rare hereditary condition affecting hundreds of Australians, causing recurring tumours throughout the body with no cure available. The breakthrough drug Belzutifan has transformed treatment for patients like Lana Hallowes, eliminating the need for constant surgeries and offering hope for the future. The medication, now listed on the Pharmaceutical Benefits Scheme for $25 per month, previously cost up to $12,000 monthly, though advocates emphasise the need for continued research into neuroendocrine cancers. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.
1000 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de 7News Just In!